CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Using index level provides a macro view of market direction, helping you balance stock-specific decisions with overall sentiment.
27,685 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
OpenClaw’s popularity surge is lifting the stock of a niche hobbyist computer maker, signaling growing demand for mod...
New research arms Americans with a dollar figure for time-wasting frictions across services, healthcare, and deliveri...
Meta unveils a sweeping 5-GW AI data center expansion in rural Louisiana, widening a rift over economic benefits and ...
XRP’s on-chain activity jumped to about 2.75 million daily transactions, while the token’s price stayed stubbornly ra...
UiPath shares fell about 6% after a strong earnings print, prompting analysts to debate whether the AI automation the...
In the latest quarter, many hedge funds bought stakes in RidgePoint Heavy Equipment, a niche rental firm. The move si...
A fresh AI memory stock is gaining momentum as hyperscalers scramble for high-bandwidth memory. Analysts say it could...
AI progress hinges not just on GPUs but on the speed and efficiency of data delivery. This deep dive explains why opt...
June offers a chance to get ahead of summer volatility. This article outlines four practical retirement moves to make...
Salesforce has long been a growth leader in cloud software, but recent performance has cooled. This guide dives into ...
As leveraged ETFs surge in popularity, the active trader dominates turnover in these products, reshaping how markets ...